Roger Berg
Baxter International
5 Papers
62 Citations
Roger Berg is an academic researcher from Baxter International. The author has contributed to research in topics: Antibody & Antibody titer. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012
TL;DR: Dose levels and total IVIG dose administered are examined to identify possible patient and product risk factors for intravenous immune globulin (IVIG)‐associated hemolysis, a recognized side effect of IG therapy.
37
Anti-A and anti-B titers in donor plasma, plasma pools, and immunoglobulin final products.
TL;DR: The purpose of this study was to determine the prevalence of high‐titer IgG anti‐A and anti‐B in plasma donors and investigate if there is any advantage of excluding these donors from the donor pool to limit anti-A andAnti‐B content in IVIG product.
19
Hemolytic events after the administration of lyophilized versus liquid immune globulin: an analysis of a single manufacturer's safety database.
TL;DR: The aim of this study was to evaluate the relationship of hemolytic events to product presentation (liquid versus lyophilized) and to examine the relationship between total IG doses administered and the individual isohemagglutinin titers of IG lots infused.
9
ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin- Free Method] Post-Authorization Safety Surveillance (PASS): Safety and Efficacy Following Product Switch in Routine Clinical Practice.
Huong Luu,Gerald Spotts,H. Gajek,Alex Kriukov,Roger Berg,Darby Stephens,Kerry Barker,Bruce M. Ewenstein +7 more
TL;DR: Results from the US and EU PASS registries validate the ADVATE safety and efficacy profile in the general hemophilia A population, in real-world clinical settings and demonstrate low risk for inhibitor development in PTPs.
2
Thromboembolic events associated with immune globulin preparations: spontaneous pharmacovigilance data versus claims-based data.
Roger Berg,Richard I. Schiff +1 more
TL;DR: The results confirmed that the Se FUT2 mutation A385T does not result in a nonsecretor allele and the use of purified clotting factor concentrates in hemophilia is recommended.
1